Immix Biopharma, Inc. (IMMX)Healthcare | Biotechnology | Los Angeles, United States | NasdaqCM
10.09 USD
+10.09
(0.000%)
⇧
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:33 p.m. EDT
IMMX is in a high-conviction consolidation-to-breakout phase driven by positive catalyst alignment (Morgan Stanley upgrade, $100M capital raise) and aggressive retail/insider buying. The options market is distinctly bullish, with speculators positioning for a move above the recent highs rather than a collapse, despite the company's negative earnings. The low short ratio and strong recent price action suggest the shorts are trapped or exiting, fueling a potential parabolic move, making this a momentum play rather than a value play until breakeven earnings are confirmed. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.419868 |
| MSTL | 0.546193 |
| AutoETS | 0.548197 |
| AutoARIMA | 0.548199 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 53% |
| H-stat | 3.03 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.711 |
| Excess Kurtosis | -0.25 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.144 |
| Market Cap | 534,892,032 |
| Forward P/E | -13.87 |
| Beta | 0.21 |
| Website | https://www.immixbio.com |
As of April 18, 2026, 10:33 p.m. EDT: Options flow is heavily skewed towards long skew (calls) over the near-term expirations, particularly the April 17th ATM and out-of-the-money strikes. Call Open Interest (85) significantly exceeds Put Open Interest (738 for the deep OTM strike 7.5, but 196 ATM vs 538 total OTM calls across all strikes implies a bullish net positioning relative to the price). The massive volume and OI at the $7.5 ATM strike for the April 17 expiration suggests a floor being established near current levels, while significant OTM call positioning targets the upside momentum. Implied volatility is low for calls (0.52-0.85) indicating complacency or a trend-following setup, whereas put IV is elevated (3.2) reflecting a distinct asymmetry in pricing a downside crash compared to a moderate uptrend.
| Attribute | Value |
|---|---|
| 52 Week Change | 4.9005847 |
| Address1 | 11,400 West Olympic Boulevard |
| Address2 | Suite 200 |
| All Time High | 11.61 |
| All Time Low | 0.68 |
| Ask | 12.8 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 681,040 |
| Average Daily Volume3 Month | 825,304 |
| Average Volume | 825,304 |
| Average Volume10Days | 681,040 |
| Beta | 0.206 |
| Bid | 7.33 |
| Bid Size | 2 |
| Book Value | 1.771 |
| City | Los Angeles |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 10.09 |
| Current Ratio | 10.013 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 10.35 |
| Day Low | 9.8712 |
| Debt To Equity | 1.144 |
| Display Name | Immix Biopharma |
| Earnings Timestamp End | 1,755,288,000 |
| Earnings Timestamp Start | 1,754,942,400 |
| Ebitda | -29,710,668 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -14.644 |
| Enterprise Value | 435,075,840 |
| Eps Current Year | -0.77 |
| Eps Forward | -0.7275 |
| Eps Trailing Twelve Months | -0.89 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.8626 |
| Fifty Day Average Change | 1.2273998 |
| Fifty Day Average Change Percent | 0.13849206 |
| Fifty Two Week Change Percent | 490.05847 |
| Fifty Two Week High | 11.61 |
| Fifty Two Week High Change | -1.5199995 |
| Fifty Two Week High Change Percent | -0.13092159 |
| Fifty Two Week Low | 1.61 |
| Fifty Two Week Low Change | 8.4800005 |
| Fifty Two Week Low Change Percent | 5.267081 |
| Fifty Two Week Range | 1.61 - 11.61 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,639,665,000,000 |
| Float Shares | 36,452,851 |
| Forward Eps | -0.7275 |
| Forward P E | -13.869415 |
| Free Cashflow | -13,612,449 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.22006 |
| Held Percent Institutions | 0.48311 |
| Implied Shares Outstanding | 53,012,092 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-12-16 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California. |
| Long Name | Immix Biopharma, Inc. |
| Market | us_market |
| Market Cap | 534,892,032 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_417356223 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -29,438,612 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 534,892,008 |
| Number Of Analyst Opinions | 5 |
| Open | 10.29 |
| Operating Cashflow | -23,930,304 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 310 651 8041 |
| Previous Close | 0.0 |
| Price Eps Current Year | -13.103897 |
| Price Hint | 2 |
| Price To Book | 5.697346 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.931 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 10.09 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 10.35 |
| Regular Market Day Low | 9.8712 |
| Regular Market Day Range | 9.8712 - 10.35 |
| Regular Market Open | 10.29 |
| Regular Market Previous Close | 0.0 |
| Regular Market Price | 10.09 |
| Regular Market Time | 1,776,715,201 |
| Regular Market Volume | 568,432 |
| Return On Assets | -0.29303 |
| Return On Equity | -0.55000997 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 53,012,092 |
| Shares Percent Shares Out | 0.0588 |
| Shares Short | 3,115,947 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 2,970,886 |
| Short Name | Immix Biopharma, Inc. |
| Short Percent Of Float | 0.0766 |
| Short Ratio | 3.59 |
| Source Interval | 15 |
| State | CA |
| Symbol | IMMX |
| Target High Price | 23.0 |
| Target Low Price | 14.8 |
| Target Mean Price | 17.56 |
| Target Median Price | 15.0 |
| Total Cash | 100,409,424 |
| Total Cash Per Share | 1.896 |
| Total Debt | 1,072,964 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | NaN |
| Trailing Eps | -0.89 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.916675 |
| Two Hundred Day Average Change | 5.173325 |
| Two Hundred Day Average Change Percent | 1.0522 |
| Type Disp | Equity |
| Volume | 568,432 |
| Website | https://www.immixbio.com |
| Zip | 90,064 |